Colgate-Palmolive Company (CL) grew with the stock adding 1.13% or $0.76 to close at $67.86 on active trading volume of 5.13M compared its three months average trading volume of 3.43M. The New York New York 10022 based company operating under the Personal Products industry has been trending up for the last 52 weeks, with the shares price now 7.93% up for the period and up by 3.7% so far this year. With price target of $72.2 and a 13.01% rebound from 52-week low, Colgate-Palmolive Company has plenty of upside potential, making it a hold with a view buy.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
SLM Corporation (SLM) gained $0.08 to close the day at a new closing price of $11.04, a 0.73% increase in value from its previous closing price that moved the stock 116.9% above its 52 week low of $5.34. A total of 5.12M shares exchanged hands during the day compared with its three month average trading volume of 4.39M. The stock, which fluctuated between $10.87 and $11.16 during the day, currently situated -5.24% below its 52 week high. The stock is up by 1.28% in the past one month and up by 53.76% over the past three months. With a one year target estimate of $12.65 and RSI of 52.41, the stock still has upside potential, making it a hold for now.
SLM Corporation, together with its subsidiaries, operates as a saving, planning, and paying for education company in the United States. It offers private education loans to students and their families. The company also provides banking products, such as certificates of deposits, money market deposit accounts, and high yield savings accounts; and a consumer savings network that offers financial rewards on everyday purchases to help families save for college. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.
Novavax, Inc. (NVAX) shares were up in last trading by 3.65% to $1.42. It experienced lighter than average volume on day. The stock decreased in value by almost -0.7% over the past week and grew 1.43% in the past month. It is currently trading 5.08% above its 50 day moving average and -67.73% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -83.27% decrease in value from its one year high of $8.49. The RSI indicator value of 55.02, lead us to believe that it is a hold for now.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.